Repeat screening cuts PCa mortality in 16-year European study

  • Hugosson J & al.
  • Eur Urol
  • 26 Feb 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • PSA screening significantly reduces deaths from prostate cancer (PCa) showing larger absolute benefit with longer follow-up.

Why this matters

  • Repeated screening may reduce PCa mortality on a population level.

Study design

  • 16-year follow-up of the European multinational ERSPC study.
  • 162,389 men (age, 55-69 years) were randomly assigned to a screening group that was offered PSA screening every 4 years or to a control group that did not receive screening.
  • Funding: Hybritech Inc.

Key results

  • Median follow-up: 15.5 years.
  • Cumulative PCa-specific incidence was 13.3% in the screening group and 10.3% in the control group.
  • Screening group had 20% lower rate of PCa mortality vs control group (rate ratio, 0.80; P<.001>
  • From 13 years follow-up:
    • difference in absolute PCa mortality between groups increased from 0.14% to 0.18% at 16 years,
    • number needed to screen (NNS) to prevent 1 PCa death reduced from 742 to 570 years,
    • number needed to diagnose (NND) decreased from 26 to 18.
  • Men with PCa detected during the first round had a:
    • higher prevalence of PSA >20 ng/mL vs second round (10% vs 4.1%; P<.001 and>
    • higher PCa mortality (HR, 1.86; P<.001 vs subsequent rounds.>

Limitations

  • Uptake of opportunistic screening could underestimate the true effects of screening.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit